Saghmos Partners with DCRI to Enhance Phase 3 Cardio-Renal Trial

Saghmos Therapeutics, a biopharmaceutical firm, has announced a strategic partnership with the Duke Clinical Research Institute (DCRI) to enhance and operationalize the Phase 3 clinical trial of their cardio-renal metabolic modulator, ST-62516. The collaboration aims to mitigate the risks of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) following contrast procedures like percutaneous coronary intervention (PCI). The FDA approved Saghmos’ Investigational New Drug (IND) application for ST-62516 in 2023.
The DCRI, renowned for its cardiovascular research, will contribute its academic and clinical leadership to the project. Anna Kazanchyan, Saghmos' CEO, expressed enthusiasm for the collaboration, highlighting the DCRI's expertise in conducting significant cardiovascular studies. Schuyler Jones, the principal investigator at DCRI, emphasized the high unmet need for treatments addressing AKI and its cardiac and renal consequences in PCI patients with pre-existing conditions such as cardiovascular disease, kidney disease, and diabetes.
Over a million PCI procedures are conducted annually in the US, with many patients having conditions that increase the risk of AKI and MACKE, creating a significant medical need. ST-62516 has the potential to benefit all PCI patients by reducing the likelihood of these complications. The DCRI is a leading academic clinical research organization, conducting innovative trials and providing comprehensive research services globally. Saghmos Therapeutics, with its issued US patent for ST-62516, is focused on developing treatments for cardiorenal complications post-PCI and has recently expanded its leadership team with key appointments.

Saghmos Therapeutics is advancing its development of ST-62516, a compound designed to lessen the chances of AKI and MACKE in patients undergoing PCI. The company has teamed up with the DCRI to refine the Phase 3 trial's planning and execution. The DCRI's extensive experience in cardiovascular research will be instrumental in this collaboration, as they bring a wealth of knowledge and operational acumen to the table.